key: cord-0706050-6g8tywjk authors: Alcázar-Arroyo, Roberto; Portolés, José; López-Sánchez, Paula; Zalamea, Felipe; Furaz, Karina; Méndez, Ángel; Nieto, Luis; Sánchez-Hernández, Rosa; Pizarro, Soledad; García, Alicia; Pereira, Mónica; Gallego-Valcárcel, Eduardo; Llópez-Carratala, María Rosario; Gironés, Ignacio Gadea; Martín, Roberto; Miranda, Blanca title: Rapid Decline of Anti-SARS-COV-2 Antibodies in Patients on Hemodialysis. The COVID-FRIAT Study date: 2021-03-09 journal: Clin Kidney J DOI: 10.1093/ckj/sfab048 sha: 93738406650f494e27e006eb2727d5a47315bcec doc_id: 706050 cord_uid: 6g8tywjk BACKGROUND: COVID-19 patients on hemodialysis (HD) have high mortality. We investigated the value of RT-PCR and the dynamic changes of antibodies (ELISA IgM+IgA and IgG) in a large HD cohort. METHODS: Prospective observational study in ten Madrid HD centers. Infection rate, anti- SARS-CoV-2 body dynamics and the incidence of asymptomatic SARS-CoV-2 infection (defined by positive RT-PCR, IgM-IgA or IgG) were assessed. RESULTS: From March 1 to April 15, 2020, 136 (16.8%) of 808 HD patients were diagnosed of symptomatic COVID-19 by nasopharyngeal RT-PCR and 42/136 (31%) died. In the second fortnight of April, RT-PCR and anti-SARS-CoV-2 antibodies were assessed on 763 of the surviving patients. At this point, 69/91 (75,8%) symptomatic COVID-19 patients had anti-SARS-CoV-2 antibodies. Four weeks later, 15.4% (10/65) of initially antibody positive patients had become negative. Among patients without prior symptomatic COVID-19, 9/672 (1.3%) were RT-PCR positive and 101/672 patients (15.0%) were antibody positive. Four weeks later, 6224/86 (72.1%) of initially antibody positive patients had become negative. Considering only IgG tittles, serology remained positive after four weeks in 90% (54/60) of patients with symptomatic COVID-19 and in 52.5% (21/40) of asymptomatic patients. The probability of an adequate serologic response (defined as the development of anti-SARS-CoV2 antibodies that persisted at 4 weeks) was higher in patients who had symptomatic COVID-19 than in asymptomatic SARS-CoV2 infection (OR 4.04 [2.04-7.99] corrected for age, Charlson score and time on HD. Living in a nursing home (5.9 [2.3-15.1]) was the main risk factors for SARS-CoV2 infection CONCLUSION: The anti-SARS-CoV-2 antibody immune response in HD patients depends on clinical presentation and the antibody titers decay earlier than previously reported for the general population. This inadequate immune response raises questions about the efficacy of future vaccines. The coronavirus disease 2019 (COVID- 19) pandemic is a threat to global health and, especially to vulnerable groups such as patients undergoing renal replacement therapy in hemodialysis (HD) centers. Patients on HD have high COVID-19 mortality rate (24.9% in Spain) 1 . In addition, they are at higher risk for COVID-19, since they attend at HD facility 2 to 6 times a week, in most cases in shared healthcare transportation, spend more than 4 hours in these units, and may live in nursing homes. In 40% of HD patients COVID-19 infection is asymptomatic, increasing the risk of nosocomial infection in HD units 2, 3 . Therefore, strict protocol measures for early detection of SARS-CoV-2 infection in HD patients have been established. They include triage at the center entrance and isolation and reverse transcriptase polymerase chain reaction (RT-PCR) test in any patient with suspected infection 4 . The role of serology is unknown, since the information available on the prevalence and the dynamic of the antibody response to SARS-CoV-2 infection in HD patients is scarce 3, 5-7. On February 28, 2020, the first case of COVID-19 was reported in Madrid, the Spanish region (6 663 394 inhabitants) most affected by COVID-19 with 348 954 cases diagnosed by RT-PCR and 12 225 deaths as of November 23, 2020. The first pandemic peak was on March 30, 2020 with a peak incidence (14-day cumulative COVID-19 cases) of 422 cases / 100 000 inhabitants 8 . And according to data from the Madrid Society of Nephrology (SOMANE) as of June 18, 2020, 509 (14.7%) of the 3 473 prevalent HD patients in Madrid would have been infected by SARS-CoV-2 9 . Without a specific vaccine or preventive treatments in a pandemic that involve a high percentage of asymptomatic patients, it is necessary to establish strategies that allow early detection of infected cases in dialysis units in order to organize health care while minimizing the risk of nosocomial infection. For this purpose, periodic serum antibodies and/or RT-PCR test have been proposed for asymptomatic patients 6 . However, the usefulness of these strategies and the dynamics of anti-SARS-CoV2 antibodies in HD patients remains unknown. Thus, there is few data on the frequency of anti-SARS-CoV2 antibodies development and antibody duration in HD patients. This information is critical to establish detection, isolation and follow-up plans. The objectives of this study were to assess SARS-CoV-2 infection by RT-PCR and serology, the prevalence of asymptomatic SARS-CoV-2 infection and the dynamics of the antibody response to SARS-CoV-2 in a large representative sample of HD patients from Madrid hospitals and dialysis centers. This is an observational, open, prospective, multicenter study in all HD patients from ten HD facilities, 8 managed by the Fundación Renal Íñigo Álvarez de Toledo (FRIAT) (4 hospitals and 4 outpatient dialysis facilities) and two hospitals Community of Madrid public health system. During the six week period after the onset of pandemic, specific triage strategy was used in every dialysis session to identify symptoms of COVID-19 or exposure to SARS-Cov-2 infected patients. One hundred thirty-six were diagnosed as symptomatic COVID-19. All HD patients over 18-year-old on April 15, 2020, were invited to participate in the study that included a baseline SARS-CoV-2 RT-PCR and anti-SARS-CoV-2 serum antibody test and a second antibody test four weeks later. The only exclusion criterion was reject to participate in the study. Patients were classified as having prior symptomatic COVID-19 diagnosed before April 15 or not. Those without a previous COVID-19 diagnosis and with a basal positive RT-PCR or serology (IgG, IgA+IgM or both) were classified as asymptomatic SARS-CoV-2 infection, others were defined as no evidence of previous or actual SARSCoV2 infection (Fig1). For patients with prior COVID-19, only anti-SARS-CoV2 antibodies were measured. At the time of the first serology, the accumulated incidence of COVID-19 infection in 14 days in the Community of Madrid was 251 cases per 100 000 inhabitants, whereas at the time of the second assessment, four weeks later, the accumulated incidence had dropped to 28 cases per 100 000 inhabitants as a result of the strict confinement adopted by the national authorities. The peak accumulated incidence in the first COVID-19 pandemic wave in the Community of Madrid was 422 cases per 100 000 inhabitants on April 6, 2020 12 . The outcome of interest was an adequate serological response, defined as the development of anti-SARS-CoV2 antibodies that persisted at 4 weeks. Data were obtained by two investigators from each center. Nasopharyngeal swabs were assessed for SARS-CoV-2 RNA by qRT-PCR real-time amplification, using specific oligonucleotides and a fluorescence-labeled probe that hybridized with a conserved target region of the ORF1ab and N genes (VIASURE SARS-CoV-2 RT-PCR Kit, CerTest Biotec, SL and TaqPathTM COVID-19 CE-IVD RT-PCR Kit, Thermo Fisher). Serum was tested for anti-SARS-CoV-2 IgA + IgM and for anti-SARS-CoV-2 IgG antibodies using an indirect enzyme immunoassay (ELISA, Vircell, Granada, Spain). The assay uses specific SARS-CoV-2 antigens from the Spike (S) glycoprotein and the nucleus-capsid (N). Samples were diluted 1:20 in sample buffer and incubated at 37°C for 60 minutes in a 96-well microtiter plate followed by protocol washing and incubation cycles, including controls and required reagents. Optical density (OD) was measured at 450 nm using a Virclia microplate reader (Vircell Spain, Granada, Spain). The ELISA results are expressed as Optical Density (OD450-OD620) measurements using a microplate reader with a 450nm filter and a 620 nm reference filter and interpreted according to the manufacturer's protocol. The OD index results are the ratio = OD of the clinical sample/OD of the calibrator, without units. The use of indexes allows to compensate interassay variability. Anti-SARS-CoV-2 antibodies detected by this assay were shown to have neutralizing (potentially protective) properties in Plaque Reduction Neutralizing Tests 10 . The sensitivity and specificity reported by the manufacturer are 88 and 99% for the combined IgM + IgA and 85 and 98% for IgG, without specific data for HD patients. All serological samples were tested in the same reference laboratory. The past history of COVID-19 and outcomes before the start of the study were recorded for all prevalent dialysis patients in participating units as of March 1, 2020 to determine the baseline exposure to the virus and estimate mortality rate. Demographic (age, sex, dialysis vintage, etiology of kidney disease), and morbidity data, including body mass index, hypertension, chronic obstructive pulmonary disease (COPD), diabetes, smoking, active neoplasms, and treatment with renin-angiotensinaldosterone system blockers were collected. Risk factors for SARS-Cov-2 infection were also recorded (healthcare transportation, known exposure to an infected partner, living in nursing homes). Data are shown as mean (standard deviation) or percentage, according to the type of variable analyzed. We use the chi-square test for association between qualitative variables and the Student's-t test for quantitative variables. The 95% confidence interval for proportions was calculated using Wald method and a p-value less than 0.05 was consider statistically significant. A logistic regression multivariate analysis was used to explore factors associated to asymptomatic positive RT-PCR test or serologic response, using a change-in-estimate criterion; a 10% cutoff was considered to identify possible confounders. Missing data were excluded from analysis. The statistical analysis was performed using As of March 1, 2020, there were 808 prevalent HD patients in the 6 hospitals and 4 outpatient dialysis centers. Up to April 15, 2020, (baseline date) 136 (16.8%) patients had been diagnosed of COVID-19 11. This would be equivalent to an accumulated incidence of 5147 cases/ 100 000 patients, much higher than the maximum accumulated incidence recorded in Madrid (422/100 000 inhabitants) during the first pandemic wave. Infection rates were not homogeneous for different centers, but this was also the case for the general population living in the same healthcare areas. COVID-19 mortality among HD patients was 42/136 COVID-19, corresponding to an estimated mortality for the Madrid HD population of 30.9%, 95% confidence interval (CI 95%) 23.1-38.6 % ( Figure 1 ). From April 15, 2020, 763 patients were included in the study, representing 99.6% of all HD patients older than 18 years of the participating centers. Patients were classified in two groups: symptomatic COVID-19 (n = 91) if diagnosed with COVID-19 prior to study entry or no COVID-19 (n = 672) ( Figure 1 ). Symptomatic COVID-19 patients were older, had more risk factors for COVID-19 (including living with an infected partner, living in nursing homes, using shared ambulance transportation and previous hospital admissions) and received angiotensin converting enzyme inhibitors more frequently (Table 1) . In the 91 patients with symptomatic COVID-19, the mean time from COVID-19 diagnosis to baseline serology was 28. In both symptomatic and asymptomatic patients with baseline anti-SARS-CoV2 antibodies, the initial IgG levels (OD Index: 6.6 SD 2.5 vs 3.6 SD 2.5; p<0.001) declined at 4 weeks (OD Index: 4.0 SD 2.9 vs 6.0 SD 2.7; p<0.001). The fall in IgG levels was less frequent in COVID-19 patients than in asymptomatic SARS-CoV2 infected patients (12.0% vs 51.6%; p<0.001) We performed a logistic regression analysis to explore differences between patients with persistent anti-SARS-CoV2 antibodies (adequate serologic response, n=79) or with transient antibodies (inadequate serologic response, n=94). The probability of an adequate serologic response was higher in patients who had symptomatic COVID-19 than in asymptomatic SARS-CoV2 infection (OR 4.04 [2.04-7.99] corrected for age, Charlson score and time on HD. In patients with COVID-19, the mean time from diagnosis to baseline antibody assessment was 28. (Table 3) . Discrepancies may depend on different assays or heterogeneity of the population studied, as more severe disease has been associated to higher and more stable neutralizing antibody titers than asymptomatic infection 25 . The impact of the present findings on long-term risk of reinfection should be studied. Confirmed COVID-19 reinfections of variable severity have been observed, including in a HD patient with previous asymptomatic infection 26 . In another published COVID-19 reinfection in a patient with preserved renal function, the disappearance of IgG antibodies before reinfection was documented 27 . It is still too early to know if these are anecdotal reports or if the risk of reinfection in patients who have lost the antibody titer is really significant, or if there is a specific antibody titer that implies protection against reinfection. Indeed, as for other viral diseases, the absence of antibody detection may not imply the absence of protective immunity 28 . In fact, SARS-CoV-2 infection generates longlasting memory B cells against several viral proteins, guaranteeing lasting B cell immunity even if antibody titers decay 29 . The risk of reinfection needs to be further explored due to its impact on future vaccination policies. The lower SARS-CoV-2 seroconversion rate and faster anti-SARS-CoV2 antibody titer decay in HD patients may be related to impaired natural and adaptive immunity in chronic kidney disease which negatively impacts every step of the immune response, from antigen presentation by monocytes, to T helper and cytotoxic cell responses, and the development of long-lasting memory B cells 30 . Furthermore, dialysis worsens the chemotactic and phagocytic function of neutrophils 31 . These impaired responses lead to the suboptimal immune response to infections and the inadequate antibody production following vaccination observed in the dialysis population. The findings of the present study suggest an inadequate immune response to SARS-CoV-2 in HD, and the need to be alert to possible reinfections, or inadequate response rates to vaccination programs. Until these issues are clarified, the current policies of screening at the admission and respiratory isolation in all HD facilities should be maintained. The results of present study identify a need to redefine the role of anti-SARS-CoV-2 antibody testing in HD patients to reduce the risk of infection and to help manage the dialysis stations occupancy. At times of high community transmission, patient screening using both RT-PCR plus serology is more efficient than RT-PCR alone, by detecting more asymptomatic potentially infective patients. RT-PCR + IgM measurement increased the sensitivity of detection of active infection to 98.6% compared to only 51.9% if just a single RT-PCR test is made 32 . In addition, the rapid disappearance of antibodies in asymptomatic patients on HD suggests that periodic serology screening and systematic data collection may allow an easy traceability of the antibody status in each patient, something similar to current practice for hepatitis B and C viruses. The knowledge of the SARS-CoV-2 status would be useful to confirm reinfections, distribute patients in the dialysis units according to the risk of contagion, and planification of vaccination campaigns. The periodicity of serological screenings will depend on the epidemiological situation at each moment, being more frequent at times of high community transmission rates. COVID-19 is more frequent in HD than in peritoneal dialysis patients, or kidney transplant recipients 1 . Transmission within HD facilities may contribute to this difference, although universal protection measures minimize the risk of nosocomial infection 33 -Alicia Sánchez García, Nephrology Department, University Hospital Puerta de Hierro, Majadahonda, Spain. -David Hernán, Fundación Renal Íñigo Álvarez de Toledo (FRIAT), Madrid, Spain. -Mónica Sánchez, Fundación Renal Íñigo Álvarez de Toledo (FRIAT), Madrid, Spain. -Jesús Portillo, Fundación Renal Íñigo Álvarez de Toledo (FRIAT), Madrid, Spain. Authors declare that they have no relevant financial interest in the scope on this study. The results presented in this paper has not be presented previously in whole or part. Fig 1. Flow-chart. Missing data is due to change of dialysis facility (n=38) or inadequate blood sample for analysis (n=61). Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN) High prevalence of asymptomatic COVID-19 in haemodialysis: learning day by day in the first month of the COVID-19 pandemic High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening Management of the SARS-CoV-2 (COVID-19) coronavirus epidemic in hemodialysis units Serologic Detection of SARS-CoV-2 Infections in Hemodialysis Centers: A Multicenter Retrospective Study in Wuhan, China The Spectrum of Clinical and Serological Features of COVID-19 in Urban Hemodialysis Patients The cumulative rate of SARS-CoV-2 infection in Chinese hemodialysis patients Incidencia de COVID-19 en la Comunidad de Madrid. Webinar SOMANE COVID-19 Clinical performance of different SARS-CoV-2 IgG antibody tests Estimation of global case fatality rate of coronavirus disease 2019 (COVID-19) using meta-analyses: Comparison between calendar date and days since the outbreak of the first confirmed case Situación de COVID-19 en España a 16 de abril de 2020. Equipo COVID-19 COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain COVID-19 and its impact on nephropathic patients: the experience at Ospedale "Guglielmo da Saliceto" in Piacenza Chronic kidney disease is the key risk factor for severe COVID-19. A call to action by the European Renal Association Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak Immune response following infection with SARS-CoV-2 and other coronaviruses: A rapid review A longitudinal, 3-month serologic assessment of SARS-CoV-2 infections in a Belgian hemodialysis facility Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild COVID-19 Loss of Anti-SARS-CoV-2 Antibodies in Mild COVID-19 Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak. Virol Sin Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections COVID-19 in a Patient with End-Stage Renal Disease on Chronic in-Center Hemodialysis after Evidence of SARS-CoV-2 IgG Antibodies. Reinfection or Inaccuracy of Antibody Testing Serum antibody profile of a patient with COVID-19 reinfection Antibody Responses to SARS-CoV-2: Let's Stick to Known Knowns Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit. mBio Aspects of immune dysfunction in end-stage renal disease Vaccination in chronic kidney disease Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) Protocol against coronavirus diseases in patients on renal replacement therapy: Dialysis and kidney transplant The keys to control a COVID-19 outbreak in a haemodialysis unit Anti-SARS-CoV-2 Ab Pos Percentage (%) Percentage (%) A Previous COVID-19 B Non previous COVID-19 The authors thank Dr. Joaquín Mendoza and Dr. José Rojas from Vircell Labs.The authors gratefully acknowledge the cooperation of every health professional fighting against COVID-19 pandemic.